Core Insights - The company reported a significant decline in revenue and net profit for the first half of 2025, with total revenue at 2.261 billion yuan, down 19.57% year-on-year, and net profit attributable to shareholders at 221 million yuan, down 35.38% [1] - The decline in revenue is primarily attributed to a decrease in the skin science innovation transformation business, which saw a revenue drop of 33.97% [1] Revenue Breakdown - The raw material business generated revenue of 626 million yuan, a slight decrease of 0.58%, accounting for 27.70% of the company's main business revenue [1] - The medical terminal business reported revenue of 673 million yuan, down 9.44%, representing 29.77% of the main business revenue [1] - The skin science innovation transformation business earned 912 million yuan, down 33.97%, making up 40.36% of the main business revenue [1] - The nutrition science innovation transformation business, under Huaxi Dangkang, achieved revenue of 38 million yuan, an increase of 32.40% [1] Product Portfolio - The company offers medical beauty products under two main brands, "Runbaiyan" and "Runzhi," covering a range of applications from skin care to layered anti-aging [2] - The core brand Runzhi has launched multiple products targeting different skin layer needs, including Runzhi Natural, No. 2, No. 3, No. 5, Feiran Needle, and Yaoran Needle [2] - The company has developed a matrix of compliant skin care products based on in-depth research of extracellular matrix (ECM) effects on aging, including Runbaiyan·Glass, Runzhi·Tito, Runzhi·Gege, and Runzhi Doll Needle [2] - Runzhi Zhenhuo(®) is marketed for post-operative skin care, providing a comprehensive solution to enhance customer and consumer satisfaction through a diverse product series [2]

Core Viewpoint - The article discusses the challenges faced by the company, Xinyang, as it transitions from an online medical beauty platform to a physical clinic model, highlighting the financial struggles and competitive pressures from larger platforms like Meituan and Douyin [4][10][15]. Financial Performance - In Q2 2025, Xinyang reported total revenue of 379 million yuan, a year-on-year decline of 7.0%, and a net loss of 36 million yuan compared to a net profit of 18.9 million yuan in the same period of 2024 [4]. - The total cost for Q2 2025 was 184.6 million yuan, up 19.0% from 155.1 million yuan in the previous year [4]. - Revenue from Xinyang's core business, "Information and Appointment Services," fell to 929 million yuan in 2024, a decrease of 19.36%, accounting for 63.37% of total revenue [10][11]. Business Transition - Xinyang launched its self-operated chain of clinics, SOYOUNG CLINIC, in November 2024, with 33 locations by August 2025, aiming for 50 by year-end [5][6]. - The shift to physical clinics has led to increased competition with former clients, resulting in further declines in online business [7][8]. Competitive Landscape - Xinyang faces significant competition from Meituan, which opened nearly 3,000 new medical beauty institutions in 2024, and Douyin, which has implemented various support policies for medical beauty services [13][14]. - The competition has led to a decrease in the number of medical service providers on Xinyang's platform, impacting its revenue [11][13]. Growth of Clinic Business - The chain business generated 170 million yuan in revenue in 2024, a staggering increase of 1,206%, with Q4 revenue reaching 81.27 million yuan, up 702% [15]. - The introduction of low-priced services, such as the "童颜针" (Youthful Needle), significantly boosted Xinyang's stock price, which rose 223% in a short period [15][16]. Operational Challenges - Rapid expansion of the clinic model has led to financial burdens, particularly in second-tier cities where patient volumes are lower [20]. - The average gross margin of 24% for the clinic business is considered unsatisfactory, and the CEO acknowledged the ongoing financial losses due to the clash between new and old business models [20][21]. Customer Dynamics - The dual role of Xinyang as both a platform and a service provider raises concerns about potential conflicts of interest and customer retention [23][24]. - While the clinic's standardized operations and competitive pricing are seen as strengths, there are concerns about the quality of service and customer satisfaction [26][27]. Industry Trends - The medical beauty industry is experiencing a slowdown, with a report indicating that 57% of consumers plan to maintain or increase their spending in 2025, down from 78% in 2024 [28].

Group 1: Industry Trends - The medical beauty industry is experiencing a shift in promotional boundaries, with increased visibility through media such as the variety show "Actors Please Stand By 3" and the urban drama "In the Name of Beauty" [1][10] - The industry is facing a slowdown, with the annual compound growth rate expected to decrease from over 18.3% (2015-2024) to 13.2% in the next five years [2] - Consumer behavior shows a trend of maintaining budget while seeking better service and results, with a notable increase in repurchase frequency from 90 days last year to 64.3 days this year for Meituan's medical beauty users [2][4] Group 2: Meituan's Strategies - Meituan is enhancing its medical beauty business by launching the "North Star Medical Beauty List," which evaluates institutions and doctors based on 927 assessment points, providing reliable references for consumers [3][4] - The company has opened nearly 9,500 new medical beauty institutions on its platform this year [5] - Meituan is addressing the cost challenges faced by small and medium-sized institutions by collaborating with upstream brands to lower procurement costs [6][7] Group 3: Targeting High-End Consumers - Meituan is focusing on penetrating higher-tier consumer segments, particularly those classified as platinum and above, by offering special benefits and free services [8] - The company is leveraging external channels, such as sponsoring media content and utilizing platforms like Xiaohongshu, to attract higher spending users [9][10] - The recent relaxation of promotional boundaries in the medical beauty sector provides Meituan with broader opportunities for outreach and brand promotion [10]

Core Viewpoint - The company held an online performance briefing on August 26, 2025, to discuss its financial results and operational updates with investors [1] Group 1: Financial Performance - For the first half of 2025, the company achieved operating revenue of 863,112,643.06 yuan and a net profit attributable to shareholders of 229,656,927.58 yuan [1] - The second quarter of 2025 saw a significant revenue increase of 86.68% compared to the first quarter, indicating a recovery trend in performance [1] - The revenue composition for the first half of 2025 was 72.39% from cosmetics (62,481.77 million yuan) and 27.61% from medical devices (23,829.45 million yuan) [1] Group 2: Product and Market Updates - As of June 30, 2025, the company has obtained three Class II medical device registration certificates, including products like medical sodium hyaluronate repair patches and solutions [1] - The company reported a positive growth trend in offline sales for the first half of 2025, attributed to sales channel optimization and product price adjustments [1] - Sales on the JD platform showed significant year-on-year growth in the first half of 2025, with enhanced cooperation and product variety [1] Group 3: Corporate Structure and Future Plans - The company currently has two wholly-owned subsidiaries: Harbin Futejia Trading Co., Ltd. and Shanghai Fuirjia Technology Development Co., Ltd. [1] - The company has sufficient self-funding reserves and currently has no financing plans [1] - There are no share reductions by major shareholders or company executives at this time, with 77,529,400 shares (14.91% of total shares) being unrestricted [1]

Core Viewpoint - The company is optimistic about the growth potential of the Chinese medical beauty market, which currently has a penetration rate of less than 5%, compared to over 20% in mature markets like South Korea [1][2] Group 1: Business Transition - The company has shifted its business model from being a transaction intermediary to directly opening offline medical beauty stores, which may lead to competition with its existing clients [1][2] - The opening of offline stores has resulted in a significant conflict between new and old business lines, leading to a decline in the number of service providers subscribing to the platform [2] Group 2: Financial Performance - In the first half of 2025, the company's revenue was 676 million yuan, a decrease of 6.9% from 726 million yuan in the same period last year, with a net loss of 67.95 million yuan compared to a net loss of 600,000 yuan in the previous year [2] - The company's offline business has now surpassed its online business, becoming the largest source of revenue, with revenue from beauty treatment services reaching 144.4 million yuan, a year-on-year increase of 426.1% [3] Group 3: Future Plans - The company plans to open 50 offline stores nationwide this year, with a goal of achieving a thousand-store scale within 8 to 10 years [3] - Despite the challenges, the company believes that the growth of its chain business will offset the decline in traditional business in the long term [3]

Investment Rating - The industry rating is "Strongly Outperforming the Market" [96] Core Insights - The report highlights the "Small Happiness" consumption trend, indicating that new consumption does not rely on overall economic growth but rather on the expansion of consumption behaviors among niche groups [3][12] - The tourism sector, particularly in Changbai Mountain, has seen significant growth, with July 2025 visitor numbers reaching 810,200, a 37.8% year-on-year increase, marking a historical high for the month [4][51] - The duty-free sector is expected to benefit from the upcoming Hainan Free Trade Port's closure, which will allow visa-free entry for individuals from 85 countries, significantly increasing the user base for duty-free shopping [4][45] - The report emphasizes the potential of the "trendy play" sector, supported by recent policies aimed at stimulating consumption and industry regulation, which may favor compliant leading enterprises [5][53] - In the education sector, advancements in AI+ education are noted, with several companies launching AI-driven educational products, indicating a potential revenue surge for key players [6][63] - The medical beauty industry is undergoing optimization through refined operations, with leading institutions expected to capture more market share as new products are launched [6][73] Summary by Sections New Consumption - New consumption is characterized by emotional value rather than cost-effectiveness, with a shift from heavy asset allocation to frequent "small happiness" purchases [3][12] - The youth demographic (ages 15-24) is projected to drive consumption trends as they enter the labor market, while the adult demographic's influence is expected to diminish [15] Duty-Free and Tourism - The duty-free industry is poised for growth with the Hainan Free Trade Port's upcoming closure, enhancing the attractiveness of the region for international tourists [42][45] - Changbai Mountain's tourism data indicates a strong recovery and growth potential, particularly in the summer season [4][51] Trendy Play - The trendy play sector is expected to benefit from consumption policies and industry self-regulation, with long-term prospects for cultural products expanding overseas [5][53] Education - The AI+ education sector is gaining traction, with several companies launching innovative products that are expected to see significant revenue growth [6][63] Medical Beauty - The medical beauty industry is experiencing a shift towards refined operations, with new product launches expected to enhance market dynamics [6][73]

Summary of the Conference Call Industry Overview - The light medical beauty industry is transitioning from reliance on high-priced projects and well-known doctors to standardized, cost-effective services. New Oxygen focuses on dermatology and small store layouts to meet consumer demands for transparency in product ingredients and pricing [2][4][18]. - The competition in the upstream product market for medical beauty is intensifying, with a significant increase in the issuance of three types of certificates in China. It is expected that by 2026, more companies will launch alternative products, breaking the monopoly of a few high-priced products and leading to market scaling [2][6][7]. Company Strategy and Operations - Traditional medical beauty institutions face high marketing costs and limited profit margins. New Oxygen aims to improve profit margins by controlling marketing costs, optimizing the supply chain, and developing proprietary products. The company is also exploring a model of self-operated small clinics [2][8][9]. - The chain rate in the light medical beauty industry is expected to increase, but it requires the provision of standardized treatments and high cost-performance services. New Oxygen implements a hard discount model to maintain profit margins while offering cost-effective services [2][10]. - The operational efficiency of chain clinics is influenced by scale, density, and efficiency. New Oxygen adopts a strategy that balances breadth and depth, focusing on high-density layouts in key cities to highlight chain advantages and improve overall efficiency [2][11]. Market Dynamics - The Chinese medical beauty market has developed rapidly over the past few years, but the industry chain structure still leans towards a seller's market with low chain rates. New Oxygen recognizes the challenges and pain points in the development of medical beauty chains and plans to leverage its advantages to achieve growth [3][8]. - The rise of regenerative products like water light needles and botulinum toxin has increased the proportion of dermatology projects, which are characterized by high frequency, low risk, and suitability for small chain stores [4][5]. Financial Performance and Projections - Traditional medical beauty institutions have low profit margins, with some large institutions only achieving around 3% to 5%. Marketing costs account for 30% to 50%, along with 20% to 30% for product costs. New Oxygen aims to control marketing costs within 10% and reduce product costs through its supply chain [8][9][22]. - Currently, the net profit margin for New Oxygen's stores is approximately 10% to 15%. In the next two to three years, as the proportion of proprietary products increases, the company expects the net profit margin to rise to 15% or even 20% [22]. Customer Retention and Cost Management - New Oxygen's model leans towards benefiting consumers and achieving equity in medical beauty services. The company employs various strategies to enhance customer retention and meet the needs of price-sensitive consumers, including membership operations, promotional activities, and community engagement [18][19]. - The company maintains a cost advantage in customer acquisition primarily through user referrals and private domain operations, which account for nearly 70% of its customer acquisition strategy [21]. Future Outlook - The light medical beauty industry is naturally suited for chain penetration due to its high standardization. New Oxygen plans to expand its presence in key cities with high-density layouts to leverage chain advantages [10][11]. - The company is also testing different site selection strategies for new clinics, focusing on core business districts and popular shopping centers to optimize overall operational effectiveness [14][16]. Conclusion - New Oxygen is strategically positioned to capitalize on the evolving landscape of the light medical beauty industry by focusing on cost-effective services, optimizing supply chains, and enhancing customer engagement. The company's proactive approach to market dynamics and operational efficiency is expected to drive future growth and profitability [2][10][21].

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The retail industry is experiencing a recovery, with high growth in premium and fashionable segments, particularly in gold jewelry and beauty care [23][27] - The report emphasizes the importance of emotional consumption themes driving growth in high-quality companies within the sector [30] Summary by Sections Retail Market Review - The retail industry index rose by 4.21% during the week of August 18-22, 2025, outperforming the Shanghai Composite Index by 2.20 percentage points [12][20] - The internet e-commerce sector showed the highest growth, with a weekly increase of 7.71% [13][17] - Year-to-date, the jewelry sector has led with a 33.74% increase [13][17] Retail Insights: Mid-Year Reports - Gold jewelry companies like Laopuhuang and Chaohongji reported significant revenue growth, with Laopuhuang achieving a revenue of 12.354 billion yuan (+251.0%) and a net profit of 2.268 billion yuan (+285.8%) [23][35] - Beauty care brands such as Shanghai Jahwa and Runben also showed positive performance, with Shanghai Jahwa reporting a net profit of 266 million yuan (+11.7%) [27][38] Focus on High-Quality Companies - Investment focus includes: - Gold jewelry brands with differentiated product offerings, recommending Laopuhuang and Chaohongji [30][32] - Offline retail companies adapting to trends, recommending Yonghui Supermarket and Aiyingshi [30][32] - High-quality domestic beauty brands, recommending Maogeping and Pola [30][32] - Medical beauty product manufacturers, recommending Aimeike and Kedi-B [30][32] Company-Specific Highlights - Laopuhuang: Achieved a revenue of 12.354 billion yuan (+250.9%) and a net profit of 2.268 billion yuan (+285.8%) in H1 2025, with strong brand expansion and channel upgrades [35][36] - Runben: Reported a revenue of 895 million yuan (+20.3%) and a net profit of 188 million yuan (+4.2%) in H1 2025, focusing on expanding its product matrix [38][40] - Aiyingshi: Achieved a revenue of 1.835 billion yuan (+8.3%) and a net profit of 46.74 million yuan (+10.2%) in H1 2025, with steady store expansion [42]

Core Viewpoint - Meituan Medical Beauty is focusing on upstream supply chain solutions rather than establishing its own medical beauty clinics, emphasizing its platform identity and ecosystem role [1] Group 1: Company Strategy - Meituan Medical Beauty will not open its own medical beauty clinics, which is a long-term strategic direction [1] - The company is enhancing its supply chain by providing traceable solutions to address issues in the medical beauty industry, such as counterfeit products and lack of logistics traceability [1] - Meituan Medical Beauty aims to increase the penetration rate of medical beauty users among its members, with only 2.2% of its platinum-level users currently engaged in medical beauty services [3][4] Group 2: Industry Insights - The Chinese medical beauty industry is experiencing rapid growth, with a projected compound annual growth rate (CAGR) of 13.2% over the next five years, although this is a slowdown compared to the previous decade [3] - The number of illegal practitioners in the medical beauty industry is nine times that of compliant practitioners, and the number of black clinics is six times that of regular clinics [2] - Water light needles are the most popular injection project, with a monthly verification growth rate exceeding 106.89% [3] Group 3: Marketing and Brand Promotion - Meituan Medical Beauty is increasing its brand awareness through promotional activities, including partnerships with variety shows and dramas, which marks a shift from its previous lack of brand promotion [4] - The company is providing free medical beauty project benefits to its high-tier members to boost engagement [4]

Core Viewpoint - The A-share market is experiencing a significant upward trend, with the Shanghai Composite Index surpassing 3,800 points, marking a 10-year high, driven by multiple favorable factors and a reassessment of asset values in China [1][3]. Group 1: Economic Resilience and Policy Support - In the first half of 2025, China's economy demonstrated unexpected resilience with a GDP growth rate of 5.3%, supported by proactive macro policies and liquidity measures from the central bank [3][6]. - External uncertainties have led to a shift in global capital allocation, with funds moving from the U.S. to undervalued markets like China, as indicated by a net inflow of over 80 billion yuan in foreign capital [4][5]. Group 2: Investment Strategies and Market Dynamics - Foreign investors are increasingly viewing Chinese assets as long-term investments rather than short-term trades, with a notable shift in attitude towards "investable" assets [3][10]. - The "barbell strategy" is gaining traction among foreign investors, focusing on growth leaders and high-dividend blue-chip stocks to balance growth and income opportunities [7][9]. Group 3: Sector Preferences and Growth Opportunities - Foreign capital is particularly attracted to sectors such as technology and consumer goods, with significant inflows into Hong Kong's market, reflecting a preference for structural opportunities in these areas [7][8]. - The rise of new consumption patterns, particularly among Generation Z, is creating growth opportunities in sectors like emotional consumption, which includes trendy products and cultural exports [8]. Group 4: Valuation and Market Positioning - Current valuation levels indicate that A-shares are relatively attractive compared to H-shares, with a low premium and strong support from state-owned capital [9]. - The high dividend yield of A-shares presents a potential advantage over government bond yields, making them appealing to foreign investors seeking income [9].